• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Delta Apparel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

    10/3/23 8:02:47 AM ET
    $AGIL
    $ALXO
    $ASNS
    $AWIN
    Professional Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGIL alert in real time by email

    Gainers

    VIQ Solutions Inc. (NASDAQ:VQS) shares rose 88.5% to $0.2470 in pre-market trading after falling 18% on Monday. VIQ Solutions recently announced delisting from the Nasdaq.

    Molekule Group, Inc. (NASDAQ:MKUL) shares gained 31.4% to $0.1960 in pre-market trading.

    AgileThought, Inc. (NASDAQ:AGIL) shares rose 28.8% to $0.2060 in pre-market trading after gaining 9% on
    Monday.

    ALX Oncology Holdings Inc. (NASDAQ:ALXO) shares rose 26.8% to $6.10 in pre-market trading. ALX Oncology Holdings is scheduled to host an investor call and webcast on Oct. 3 to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer.

    SIGNA Sports United N.V. (NYSE:SSU) shares surged 22.9% to $0.1903 in pre-market trading after falling 44% on Monday. SIGNA Sports recently announced an acceleration of its strategic realignment and performance enhancement program.

    Loop Media, Inc. (NYSE:LPTV) rose 19.6% to $0.58 in pre-market trading.

    Renalytix Plc (NASDAQ:RNLX) rose 15.3% to $1.73 in pre-market trading after falling 6% on Monday. Renalytix recently reported worse-than-expected FY23 revenue results and issued FY24 guidance.

    MSP Recovery, Inc. (NASDAQ:LIFW) shares climbed 12.9% to $0.2260 in pre-market trading after falling around 7% on Monday.

    SeaStar Medical Holding Corporation (NASDAQ:ICU) gained 10.3% to $0.4601 in pre-market trading after jumping 58% on Monday. SeaStar Medical was recently granted Breakthrough Device Designation by the FDA for its Selective Cytopheretic Device for Cardiorenal Syndrome.

    Delta Apparel, Inc. (NYSE:DLA) shares jumped 8.1% to $7.12 in pre-market trading after the company said it received an unsolicited offer to purchase its Salt Life business.

    Losers

    AERWINS Technologies Inc. (NASDAQ:AWIN) fell 17.9% to $0.1880 in pre-market trading. AERWINS Technologies shares jumped around 90% on Monday after the company said it is considering strategic alternatives for its non-core operations.

    SmileDirectClub, Inc. (NASDAQ:SDC) fell 15.6% to $0.1360 in pre-market trading. SmileDirectClub received a written notice from Nasdaq that Nasdaq had determined that company's securities will be delisted from Nasdaq and suspended at opening of business on Oct. 4, 2023.

    Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) shares fell 15.6% to $2.00 in pre-market trading.

    Actelis Networks, Inc. (NASDAQ:ASNS) fell 13.6% to $1.08 in pre-market trading after gaining around 14% on Monday. Actelis recently announced it achieved Third Party Validation for FIPS cyber protection standard required by government agencies.

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) fell 10.3% to $0.2574 in pre-market trading after gaining 10% on Monday. NRx Pharmaceuticals announced FDA permission to proceed on Investigational New Drug application for NRX-101 to treat chronic pain.

    Eastside Distilling, Inc. (NASDAQ:EAST) fell 9.7% to $1.48 in pre-market trading after gaining 33% on Monday. The company recently announced the successful completion of a debt-for-equity exchange with key first and second lien debt holders.

    OpGen, Inc. (NASDAQ:OPGN) shares fell 9.6% to $0.3799 in pre-market trading after gaining 5% on Monday. OpGen recently requested to withdraw its registration statement on Form S-1.

    Better Choice Company Inc. (NYSE:BTTR) shares fell 9.6% to $0.1410 in pre-market trading after surging more than 25% on Monday.

    IceCure Medical Ltd (NASDAQ:ICCM) fell 8.9% to $0.7788 in pre-market. IceCure Medical shares jumped 54% on Monday after the company announced an independent study validated its ProSense cryoblation treatment as a safe and effective outpatient procedure for breast cancer with a 96.8% success rate.

    Femasys Inc. (NASDAQ:FEMY) fell 8% to $3.58 in pre-market trading after gaining more than 30% on Monday.

    Now Read This: McCormick, Delta Apparel And 3 Stocks To Watch Heading Into Tuesday

    Get the next $AGIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIL
    $ALXO
    $ASNS
    $AWIN

    CompanyDatePrice TargetRatingAnalyst
    ALX Oncology Holdings Inc.
    $ALXO
    3/6/2026$6.00Buy
    UBS
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    ALX Oncology Holdings Inc.
    $ALXO
    11/13/2025$4.00Buy
    Jefferies
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    ALX Oncology Holdings Inc.
    $ALXO
    3/6/2025$2.00 → $3.00Hold → Buy
    Jefferies
    ALX Oncology Holdings Inc.
    $ALXO
    12/19/2024$12.00 → $2.00Buy → Hold
    Jefferies
    ALX Oncology Holdings Inc.
    $ALXO
    3/8/2024$10.00 → $14.00Buy → Hold
    Stifel
    More analyst ratings

    $AGIL
    $ALXO
    $ASNS
    $AWIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on ALX Oncology with a new price target

    UBS resumed coverage of ALX Oncology with a rating of Buy and set a new price target of $6.00

    3/6/26 8:38:03 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw initiated coverage on Femasys with a new price target

    Laidlaw initiated coverage of Femasys with a rating of Buy and set a new price target of $6.50

    11/20/25 8:06:38 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Jefferies initiated coverage on ALX Oncology with a new price target

    Jefferies initiated coverage of ALX Oncology with a rating of Buy and set a new price target of $4.00

    11/13/25 9:09:54 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $ALXO
    $ASNS
    $AWIN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AGIL
    $ALXO
    $ASNS
    $AWIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Actelis Networks Secures Japanese Governmental Order for Cyber-Hardened Networking Solutions for Critical Infrastructure

    SUNNYVALE, Calif, March 11, 2026 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid-deployment networking solutions for IoT and broadband applications, today announced it has received a significant order from a Japanese governmental entity for the supply of dozens of units of its MetaLight networking solutions to support critical civil and defense infrastructure modernization across Japan. The order, placed through Actelis' established Japanese channel partner and distributor, will deploy dozens of the Company's proven MetaLight units across a range of critical infrastructure environments. The MetaLight family co

    3/11/26 8:45:00 AM ET
    $ASNS
    Telecommunications Equipment
    Telecommunications

    U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

    IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense®Clinical study sites may offer ProSense® cryoablation to additional patients not enrolled in the study, supporting its potential broader commercial adoptionPost-market study will be conducted using cryoprobes sold exclusively by IceCure and facilities will be able to use CPT Category III reimbursement codeCAESAREA, Israel, March 11, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surg

    3/11/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $AGIL
    $ALXO
    $ASNS
    $AWIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Klencke Barbara

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    3/5/26 4:05:06 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Klencke Barbara claimed ownership of 120,000 shares (SEC Form 3)

    3 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    3/5/26 4:01:03 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Lee-Sepsick Kathy

    4 - FEMASYS INC (0001339005) (Issuer)

    2/20/26 5:37:51 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $AGIL
    $ALXO
    $ASNS
    $AWIN
    SEC Filings

    View All

    SEC Form 6-K filed by IceCure Medical Ltd.

    6-K - IceCure Medical Ltd. (0001584371) (Filer)

    3/11/26 8:58:21 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by ALX Oncology Holdings Inc.

    10-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

    3/9/26 4:03:57 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by IceCure Medical Ltd.

    6-K - IceCure Medical Ltd. (0001584371) (Filer)

    3/9/26 8:46:08 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $AGIL
    $ALXO
    $ASNS
    $AWIN
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

    Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technolo

    2/9/26 4:30:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AGIL
    $ALXO
    $ASNS
    $AWIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    11/14/24 9:38:43 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 7:22:54 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $ALXO
    $ASNS
    $AWIN
    Financials

    Live finance-specific insights

    View All

    IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

    CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Tuesday, March 17, 2026. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Tuesday, March 17, 2026, at 11:00 am EDTUS: 1-888-407-2553Is

    3/10/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and drives durable benefit in HER2-positive cancers - - Full biomarker analysis from Phase 1b/2 evorpacept-zanidatamab combination trial accepted for poster presentation at ESMO Breast Canc

    2/27/26 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release. Fourth Quarter and Full Year 2025 Results Webcast Information Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET Webcast Access: https://viavid.webcasts.com/starthere.

    2/19/26 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care